CD4 and tuberculosis: By reframing the HIV disease variables in terms of systemic immune activation, which predicts HIV disease progression better than CD4+ T cell counts or HIV viral loads [15–17], we provide a novel paradigm for understanding the sources of pharmacokinetic variability among HIV/tuberculosis patients.